NEW YORK(GenomeWeb) – Researchers at Arizona State University's Biodesign Institute have identified an autoantibody signature that could prove useful in early detection of ovarian cancer.

Using high-density programmable protein microarrays, they identified autoantibodies to 12 protein antigens that could distinguish between ovarian cancer samples and controls. These markers are now being tested further through the National Cancer Institute's Early Detection Research Network, Karen Anderson, an ASU researcher and one of the leaders of the effort, told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.